Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Clinical Trial of GI-102 in Combination with KEYTRUDA for Immunotherapy Resistant Liver Cancer, Melanoma, and Renal Cell Carcinoma Set to Begin

Next Previous
Trial Profile

Phase 2 Clinical Trial of GI-102 in Combination with KEYTRUDA for Immunotherapy Resistant Liver Cancer, Melanoma, and Renal Cell Carcinoma Set to Begin

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GI 102 (Primary) ; Pembrolizumab (Primary)
  • Indications Liver cancer; Malignant melanoma; Renal cell carcinoma
  • Focus Therapeutic Use

Most Recent Events

  • 27 Aug 2024 New trial record
  • 26 Aug 2024 According to GI Innovation media release, the company announced that it has signed a clinical trial collaboration and supply agreement with MSD (a tradename of Merck& Co., Inc) to evaluate the combination of GI-102 and MSD anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with immunotherapy-resistant liver cancer, melanoma, and renal cell carcinoma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top